Seelos Therapeutics (SEEL)
(Delayed Data from NSDQ)
$0.28 USD
-0.01 (-3.68%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $0.30 +0.02 (7.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Seelos Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 43 | 71 | 62 | 19 | 30 |
Income After Depreciation & Amortization | -41 | -71 | -62 | -19 | -30 |
Non-Operating Income | 3 | -3 | -3 | 0 | -21 |
Interest Expense | 0 | 0 | 2 | 0 | 0 |
Pretax Income | -38 | -74 | -66 | -19 | -51 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -38 | -74 | -66 | -19 | -51 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -38 | -74 | -66 | -19 | -51 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -41 | -70 | -60 | -19 | -30 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 2 | 0 | 0 |
Income After Depreciation & Amortization | -41 | -71 | -62 | -19 | -30 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.90 | NA | 3.03 | 1.49 | 0.68 |
Diluted EPS Before Non-Recurring Items | -7.73 | NA | -21.32 | -12.91 | -41.44 |
Diluted Net EPS (GAAP) | -7.73 | -20.72 | -21.92 | -12.91 | -75.68 |
Fiscal Year end for Seelos Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.65 | 0.41 | 0.34 | 0.81 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.65 | 0.41 | 0.34 | 0.81 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 8.67 | 13.01 | 11.29 | 9.74 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -8.02 | -12.60 | -10.95 | -8.93 |
Non-Operating Income | NA | 2.61 | 23.14 | -18.54 | -4.49 |
Interest Expense | NA | 0.02 | 0.04 | 0.01 | 0.01 |
Pretax Income | NA | -5.45 | 10.50 | -29.50 | -13.43 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.45 | 10.50 | -29.50 | -13.43 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.45 | 10.50 | -29.50 | -13.43 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 4.93 | NA | 3.75 |
Diluted EPS Before Non-Recurring Items | NA | NA | -8.41 | NA | -3.60 |
Diluted Net EPS (GAAP) | NA | 6.08 | -3.60 | -6.61 | -3.60 |